Measuring oncogenic signaling pathways in cancer with PET: An emerging paradigm from studies in castration-resistant prostate cancer Journal Article
| Author: | Evans, M. J. |
| Article Title: | Measuring oncogenic signaling pathways in cancer with PET: An emerging paradigm from studies in castration-resistant prostate cancer |
| Abstract: | As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a commitment to develop technologies to this end, few investigational radiotracers directly measure the biology of common oncogenic signaling pathways often addressed by targeted therapies. Visible progress has been achieved with a handful of radiotracers rationally designed to intercalate the pathobiology of prostate cancer, a molecularly heterogeneous disease nevertheless broadly defined by a fairly small repertoire of recurrent oncogenic lesions. Significance: That variable treatment responses or emergent resistance phenotypes are often documented in humans argues strongly for diagnostic technologies that can be realistically applied posttherapy to capture the dynamic patterns of disease response. The purpose of this review is to describe a collection of radiotracers developed to measure the pathobiology of prostate cancer for improved treatment monitoring, placing particular emphasis on the biologic rationale for their preparation. A chronologic description of radiotracer development programs is outlined, primarily to stress how an ongoing dialectic between earlier and more contemporary imaging technologies has accelerated discovery. © 2012 American Association for Cancer Research. |
| Keywords: | signal transduction; unclassified drug; overall survival; review; nonhuman; positron emission tomography; colorectal cancer; prostate specific antigen; gastrointestinal stromal tumor; melanoma; ovary cancer; breast cancer; carcinoembryonic antigen; epidermal growth factor receptor 2; small interfering rna; lung cancer; molecular imaging; kidney carcinoma; prostate cancer; monoclonal antibody j591; prostate specific membrane antigen; carbonate dehydratase ix; chromatin immunoprecipitation; myc protein; lymphoma; medronate technetium tc 99m; kallikrein; radiopharmaceutical agent; heat shock protein 90 inhibitor; tracer; radioisotope; abiraterone acetate; ca 125 antigen; estrogen receptor; trastuzumab; single photon emission computer tomography; 16beta fluoro 5alpha dihydrotestosterone f 18; androgen deprivation therapy; zirconium; transferrin; androstanolone; castration resistant prostate cancer; tumor microenvironment; phase 2 clinical trial (topic); phase 1 clinical trial (topic); transferrin receptor; enzalutamide; monoclonal antibody 5a10; sodium fluoride f 18 |
| Journal Title: | Cancer Discovery |
| Volume: | 2 |
| Issue: | 11 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2012-11-01 |
| Start Page: | 985 |
| End Page: | 994 |
| Language: | English |
| DOI: | 10.1158/2159-8290.cd-12-0178 |
| PROVIDER: | scopus |
| PMCID: | PMC3508522 |
| PUBMED: | 23043150 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "Source: Scopus" |
